



Vaccines and Global Health: The Week in Review
28 June 2025 :: Issue 805
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

:: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

Editor's Note:

This edition includes extended coverage of two major events from the last week: the Gavi Summit/pledging conference in Brussels, and the U.S CDC ACIP meeting in Atlanta. We include text from various formal announcements, as well as analysis and commentary from a range of sources.

.....
.....

Gavi :: Global Summit: Health & Prosperity through Immunisation

25 June 2025 Brussels, Belgium

World leaders recommit to immunisation amid global funding shortfall

- :: The Global Summit: Health & Prosperity through Immunisation sees a **record number of donors pledge towards Gavi, the Vaccine Alliance, securing more than US\$ 9 billion towards a target budget of US\$ 11.9 billion for its next strategic period (2026–2030)**
- :: Additional commitments were made, including an **unprecedented US\$ 4.5 billion in complementary financing from development finance institutions in support of country systems** and accelerated access to vaccines, cost savings of up to US\$ 200 million from manufacturers, and more than US\$ 149 million in private sector partnerships focused on immunisation delivery
- :: With **some donors unable to pledge support at the Summit due to their domestic budgetary cycles**, Gavi will continue to work with its donors to ensure its next strategic period is fully funded, as a shortfall will leave millions of children unvaccinated and increase health security risks

[Text-bolding from original]

Brussels, 25 June 2025 – Today, at the *Global Summit: Health and Prosperity through Immunisation* in Brussels, world leaders pledged support for Gavi, the Vaccine Alliance, leading to a total of more than US\$ 9 billion secured against a targeted US\$ 11.9 billion budget for its next five-year strategic period from 2026 to 2030 (Gavi 6.0). Additional donor commitments are expected in the coming months....

Record volumes of innovative financing commitments

More than US\$ 4.5 billion in new financial instruments and partnerships were announced at the Summit. This includes US\$ 3 billion in partnerships with multilateral development banks to provide countries with flexible, long-term support as they transition from aid to self-sustained financing. Gavi will explore the development of a new MDB multiplier mechanism to increase the targeting and impact of joint investments with MDBs. A further US\$ 1.5 billion was committed to provide additional liquidity to Gavi – leveraged against existing donor pledges – should it need rapid and flexible access to capital in the event of unexpected activities, including major outbreak or health emergency.

Commitments made by development finance institutions include:

- A landmark agreement between Gavi and the **Asian Infrastructure Investment Bank (AIIB)** to scale sustainable financing, providing **up to US \$1 billion** in financing from AIIB for public-sector health projects in low- and lower-middle-income countries, and a new liquidity financing facility, providing **up to US\$ 500 million** for Gavi (and its donors), which both partners are working towards by 2026 (subject to required approvals).
- A new cooperation agreement signed by Gavi and the **Asian Development Bank (ADB)** to mobilise financing for health and immunisation in 36 countries across the Asia-Pacific region.
- An extension of the **European Investment Bank's EUR 1 billion** financing facility to support both routine immunisation and outbreak response programmes while enhancing Gavi's ability to negotiate with vaccine manufacturers and respond flexibly to global vaccination needs.

- A strengthened collaboration between Gavi and the **World Bank Group** to mobilize at least **US\$ 2 billion** over the next five years to finance primary healthcare systems and immunization - working closely with the Global Financing Facility for Women, Children and Adolescents, and depending on country demand and resource availability, and support regional vaccine manufacturing in Africa.

Vaccine manufacturers step up

As a public-private partnership, Gavi was able to secure bold commitments from some of the world's most important vaccine manufacturers at today's Summit, who announced initiatives to improve access to critical vaccines against diseases like cervical cancer, Ebola, malaria, meningitis, pneumonia and rotavirus. In addition, price reductions, made possible by manufacturers passing on lower input costs, could enable savings for Gavi-supported programmes of up to US\$ 200 million by 2030.

Commitments made by manufacturers include:

- **Bharat Biotech and GSK** announced that the price of the RTS,S/AS01 **malaria vaccine**, for children in endemic countries, would be reduced by Bharat Biotech by more than half to less than US\$ 5. The price ambition will be realised progressively, starting now and will reach its overall reduction as the transfer of vaccine production between the two companies concludes.
- **GSK** announced that a reduction in unit costs, and increased production capacity of the RTS,S/AS01 **malaria vaccine** due to enhanced manufacturing efficiencies will generate cost savings to Gavi of up to EUR 20 million, supporting Gavi's efforts to reach 50 million more children with the malaria vaccine in 2025–2030.
- **GSK** committed to a 17% price reduction for their new **rotavirus vaccines** blow fill seal presentation, which help save Gavi and implementing countries up to EUR 80 million euros, assuming constant demand and price over the period up to 2030. It will also help countries reduce their cold chain footprint by 30%, creating additional indirect cost savings.
- With supply now sufficient to meet anticipated demand thanks to expanded capacity, **MSD** will continue to offer its **HPV vaccines** to Gavi for use in Gavi-eligible countries at an access price, between 2026–2030.
- **MSD**, which is developing an investigational next-generation **Ebola Zaire vaccine** through a collaboration with Hilleman Laboratories will look to increase production process efficiency and improve product thermostability. If successful, and upon regulatory approval, this advancement could increase global supply and help facilitate access, including through the Gavi-funded global Ebola Zaire vaccine stockpile.
- **Serum Institute of India (SII)** will substantially lower the price of the R21 **malaria vaccine** during Gavi 6.0. This would represent a saving to Gavi and implementing countries of over US\$100 million, depending on the exact volumes needed and final approvals by Gavi and UNICEF.
- **SII** committed to continuing to offer the most affordable **pneumococcal conjugate vaccine (PCV)** containing most relevant serotypes, at US\$ 2 per dose to Former Gavi-eligible countries, and consistently below US\$ 4 per dose to never Gavi-eligible MICs, through 2030.
- The recent certification of **SII's multivalent meningococcal conjugate vaccine** – which protects against meningitis serogroups A, C, W, Y, and X – for use in controlled temperature chain (CTC), will allow storage outside of the cold chain for a period of 15 days, ease logistical challenges and improve access, especially in remote areas or where cold chain is limited.

The Summit also reaffirmed support to Africa's vaccine sovereignty through Gavi's African Vaccine Manufacturing Accelerator (AVMA), which will provide milestone-based financing to regional manufacturing and catalyse productive investment across the continent. AVMA is already driving impact, with technology transfer agreements underway across the continent.

Commitments announced at the Summit include:

- **Biovac**, a leading South African biopharmaceutical company, and **Biological E. Ltd**, a major global vaccine supplier from India, have signed a landmark technology transfer agreement to manufacture and distribute a pneumococcal conjugate vaccine (PCV14) across Africa, which is a priority vaccine under AVMA due to its public health impact and strategic importance for Africa.
- A new partnership between **MedAccess** and Gavi to explore the development of a mechanism that will provide **up to US\$ 50 million** in guarantee-based finance to African manufacturing projects seeking to participate in the [African Vaccine Manufacturing Accelerator](#).
- **UNICEF** announced that, by 2035, it is aiming for up to 20% of Africa's demand for eight key vaccines to be met by African WHO-prequalified manufacturers.

Private sector innovation to transform vaccine delivery

Today Gavi also welcomed an anchor US\$ 40 million investment in a new Innovation Scale Up Fund, designed to fast-track innovative delivery solutions. Including this groundbreaking initiative, new private sector partnerships worth over US\$ 149 million were announced, including collaborations to improve digital and supply chains.

Commitments made by the private sector include:

- **Grand Challenges Canada** will pledge **up to US\$ 40 million** to anchor Gavi's Innovation Scale-Up Fund, aimed at accelerating the scaling of high-impact immunisation delivery innovations, subject to the closing and final determination of the structure and size of the Fund.
- The **"la Caixa" Foundation** renews its partnership with Gavi with a EUR 9 million multi-year contribution (2025–2027), leveraging the 1=4 matching fund to make **EUR 36 million** available in total, thanks to contributions from "la Caixa" Foundation and the **Gates Foundation**, to expand child immunisation. This partnership is also working to expand geographically through the launch of the Alliance for Child Vaccination in Portugal.
- The **Children's Investment Fund Foundation (CIFF)**, **Givewell**, **Arm** and a US based foundation are partnering with Gavi, the Vaccine Alliance through the Gavi Matching Fund, with the intent to co-invest **US\$ 35 million** in a portfolio of solutions that combine innovative integrated health and nutrition models, AI-enabled digital tools and in-country capacity strengthening for scale and sustainability, subject to approval.
- **Integrate Health** and an international charity plan to mobilize **US\$ 15 million** in equal co-funding (from 2025–2030) to scale integrated primary healthcare in Guinea and another Gavi-supported country to further accelerate vaccine equity across West Africa, subject to final approvals.
- An international charity plans to contribute **US\$ 10 million** to Gavi through a Malaria Procurement Grant, aiming to reduce childhood mortality across West Africa, subject to final approvals.
- Gavi and **Zipline** continue to scale up Zipline's drone-based delivery system across Ghana, Côte d'Ivoire, Kenya, and Nigeria, supported by visionary **philanthropies** and **High-Net Worth Individuals**, and matched contributions from the **Gates Foundation**, for a total of up **US\$ 6 million**. This partnership has already enabled the delivery of over 23 million vaccine doses, accelerating equitable immunization access for millions.
- In a first multi-party collaboration with Gavi, **Temasek Foundation** joins forces with **UBS Optimus Foundation** and **Clinton Health Access Initiative** with support from the Gavi Matching Fund to support a **US\$ 4.54 million** initiative starting in Bekasi City and Bogor District, Indonesia, to reach zero-dose and under-immunized children by strengthening integrated primary health care services through digital health initiatives and comprehensive antenatal care.
- **The Bayer Foundation** has invested more than **US\$ 2 million** of catalytic funding to strengthen immunization and health service delivery for agricultural communities across Africa to date and is looking forward to further scaling its joint activities with Gavi and other partners in the region.

- The **UPS Foundation** is providing **US\$ 2 million** to continue to help strengthen supply chain networks that deliver life-saving vaccines to children in the world's poorest countries.
- **Signalytic** – an INFUSE Pacesetter 2024 – will introduce solar-powered, high-speed digital solutions in health centres in Rwanda, thanks to support totaling **US\$ 1.8 million** from **Arm, The Coca-Cola Foundation** and **Project Last Mile**.
- Additional contributions from other donors include **US\$ 100,000** from **Workday** to support INFUSE and **US\$ 175,000** from a US-based family foundation.
- **Iveco Group** and Gavi are proud to announce that a partnership is being finalized to support vaccine supply in Gavi-eligible countries within the framework of Italy's Mattei Plan, supporting the Gavi 6.0 Strategy and Italy's development objectives.
- Supported by US\$ 5.8 m from Arm and CIFF (from the abovementioned contribution) and Gavi Matching Fund, **Simprints** is deploying the world's first open-source biometric ID. This hardwareless technology, powered by AI, will link infants to their medical records, supporting malaria vaccine delivery and routine immunisation in Ghana.

[Extensive series of quotations from donors follows and is available at the title link above]

.....

Global Health Architecture

Gavi statement on the global health architecture

Brussels, 25 June 2025 –

Noting the tremendous progress in human capital and survival as a result of 25 years of international investment in health since the Millennium Development Goals, and the subsequent Sustainable Development Goals;

In view of the reduction by half of the number of children dying before the age of 5, 70% fewer child deaths from vaccine preventable disease, and life expectancy at birth having increased on average by 8 years in the Global South;

Acknowledging that while delivering this impact, these investments have at the same time created multiple agencies, initiatives and projects with increasingly overlapping mandates, inefficiencies and complexities for partner countries in the Global South;

Recognising the priority of alignment of scarce ODA expenditure with the development priorities and strategies of recipient countries, as demonstrated recently through the Lusaka Agenda;

Gavi commits to adopting – *at the Global Summit: Health & Prosperity through Immunisation co-hosted by the European Union, the Gates Foundation and Gavi on June 25, 2025* –

[i] an ambitious internal reform programme through the Gavi Leap initiative;

[ii] a commitment to deep meaningful engagement with other global health agencies to exploit synergy; and

[iii] proactive engagement in reform of the global health architecture, recognizing that the principles that drive the Gavi Leap could well act as a catalyst for reform of the global health architecture.

These commitments are predicated on the sincere belief in the urgent need to reform ourselves and of the architecture in which we operate.

PRINCIPLES FOR REFORM OF THE GLOBAL HEALTH ARCHITECTURE:

- **Country centricity:** give countries more agency, simplify processes, and promote equitable approaches with country and community needs at the heart.

- **Country sovereignty:** support countries to fully transition out of donor support.
- **Limited mandates:** agencies and institutions operating in line with their comparative advantages preventing duplication and fragmentation
- **Finite lifespans:** agencies and institutions commit to define a date to put themselves out of business and focus on global public goods.

:::::::

Gates Foundation on Gavi Summit

World Leaders Recommit to Immunisation Amid Global Funding Shortfall

Press release Jun 26, 2025

Mark Suzman's Statement on Outcome of Gavi Pledging Event

Statement Jun 25, 2025

Child Deaths Will Rise if Funding for Lifesaving Vaccine Program Falters

Press release Jun 24, 2025

Amid historic foreign aid cuts, Bill Gates urges wealthy nations to invest in Gavi, the Vaccine Alliance, which provides lifesaving vaccines to more than half of the world's children

:::::::

HHS Secretary Intervention – Gavi Summit

Gavi Statement

25 June 2025

Gavi statement in response to comments made by the United States Secretary for Health and Human Services at the Global Summit: Health and Prosperity through Immunisation, Brussels, 25 June 2025.

Seth Berkley

LinkedIn, 28 June 2025

I was pleased to be part of the Gavi replenishment and happy that donors stepped up and provided commitments of more than \$9 billion with a number of countries yet to complete their pledges. I was very sorry to hear the video from the U.S. Secretary of Health RFKjr which was outrageous and irresponsible and appreciate Richard Horton's response. Here is an interview on NPR where I have an opportunity to explain why this is bad policy:

How children will be impacted by U.S. cuts to global vaccine alliance [klcc.org](https://www.klcc.org)

:::::::

:::::::

U.S. Immunization Governance/Policy Crisis :: ACIP Meeting – June 25-26, 2025

Editor's Note:

Last week's ACIP meeting was as extraordinary as it was disappointing – "exceeding expectations" for how much damage might be done in two weeks to decades of evidence-based science considered by independent expert advisory committee members to derive responsible immunization recommendations. The CDC media release below summarizes the meeting outcomes and includes a summary statement by the new committee members available at the title link.

One positive was the oral public comment segments during which, overall, speakers challenged the integrity of the ACIP meeting and its agenda, and the credibility of the newly appointed voting members. CDC has posted the videos of both days of the meeting [You Tube links below].

Selected analysis and commentary on the ACIP meeting are also provided below. As this analysis and commentary is still emerging, we will likely include additional content in next week's edition.

ACIP Meeting – June 25-26, 2025

- [Meeting Materials](#)
- [YouTube Live Stream Link 6-25-2025](#)
- [YouTube Live Stream Link 6-26-2025](#)

[CDC's Advisory Committee on Immunization Concludes Meeting with Joint Statement](#)

ATLANTA—JUNE 26, 2025—

The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) held a meeting on Wednesday and Thursday, June 25-26, 2025, at CDC headquarters in Atlanta, Georgia. The ACIP comprises leading medical and public health experts who advise the CDC on the safety, effectiveness, and clinical necessity of vaccines.

The ACIP voted:

- To approve, by a vote of five to two, one dose of clesrovimab, a monoclonal antibody for infants whose mothers are not protected by maternal respiratory syncytial virus (RSV) vaccination. Clesrovimab is one of two RSV monoclonal antibody products available.
- To approve, by a vote of seven to zero, the updated Vaccines for Children Program resolution for prevention of RSV.
- To reaffirm recommendation, by a vote of six to zero, for routine annual influenza vaccination of all persons aged over six months who do not have contraindications.
- To recommend, by a vote of five to one, for children 18 years and younger to receive seasonal influenza vaccines only in single-dose formulations that are free of thimerosal as a preservative.
- To recommend, by a vote of five to one, that pregnant women receive seasonal influenza vaccines only in single-dose formulations that are free of thimerosal as a preservative.
- To recommend, by a vote of five to one, that all adults receive seasonal influenza vaccines only in single-dose formulations that are free of thimerosal as a preservative.

Recommendations made by the ACIP are reviewed by the CDC Director, and if adopted, are published as official CDC/HHS recommendations in the *Morbidity and Mortality Weekly Report*. The CDC Director informs the Secretary of Health and Human Services and the Assistant Secretary for Health of immunization recommendations.

The ACIP intends to hold its next meeting in the third quarter of 2025...

The members of the ACIP issued the following statement at the conclusion of today's meeting [*available at title link above*]...

.....

[Kennedy's New Advisers Rescind Recommendations for Some Flu Vaccines](#) [Critics saw in the move the beginnings of a more restrictive approach to providing vaccines to Americans.](#)

The New York Times, June 26, 2025

.....

CDC advisory panel, selected by RFK Jr., recommends thimerosal be dropped from flu vaccines

The move is a symbolic win for vaccine critics but could sow broader doubts about immunizations.

By Helen Branswell, Senior Writer, Infectious Diseases

STAT, June 26, 2025

.....

PhRMA Statement on This Week's ACIP Meetings

WASHINGTON, D.C. (June 27, 2025) – Today, Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Director of Public Affairs Andrew Powaleny issued the following statement:

"It's vital that decisions impacting vaccine recommendations and patient access are grounded in science. While it's positive to see the RSV recommendation, we remain concerned that the committee is basing recommendations related to the use of thimerosal in flu vaccines and future plans to revisit the childhood immunization schedule on theories that ignore decades of scientific evidence. We remain troubled that this type of approach could further fuel vaccine skepticism and risk patients' access to life saving vaccines."

.....

Vaccine, public health advocates warn of fallout from ACIP meeting

Chris Dall, MA

CIDRAP, U Minn, June 27, 2025

In the wake of this week's meeting of a newly reconstituted federal vaccine advisory board, public health, medical, and infectious disease experts are not holding back in their reaction to the panel's new direction, which they fear will only serve to further undermine public confidence in vaccines.

The 2-day meeting of the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) was marked by a controversial vote to recommend that all Americans receive flu vaccines only in single doses that don't contain the preservative thimerosal, which has long been a target of vaccine critics, including Department of Health and Human Services Secretary Robert F. Kennedy Jr. That vote came after a presentation on thimerosal that many observers say was filled with inaccuracies and long-debunked talking points.

The new ACIP chair also indicated that the board plans to review the entire childhood immunization schedule and use of two specific childhood vaccines...

.....

Calculating the Damage of Vaccine Skepticism

It's clear that we're on the precipice of a surge in preventable diseases. But how bad will it get?

By Rivka Galchen

The New Yorker, June 27, 2025

Since its inception, in 2000, Gavi, the Vaccine Alliance, which works with local governments to bring vaccines to low-income countries, has helped administer 1.9 billion vaccines and reached a billion children. Global vaccination work has nearly halved the global infant-mortality rate, saved more than 150 million lives, prevented innumerable costly hospitalizations and long-term disabilities, and strengthened local health services in many remote places. "I can't imagine a more successful, cost-effective public-health organization than the Gavi alliance," a pediatrician and vaccine researcher said.

In the United States, we're somewhat blinkered about what vaccination means to the other 96 per cent of people in the world. On Wednesday, the Secretary of Health and Human Services, Robert F.

Kennedy, Jr., announced that the U.S. intends to withhold the amount that the Biden Administration had pledged to Gavi, \$1.6 billion. He claimed that Gavi had “ignored the science” about vaccine safety. He had already dismissed all 17 members of the C.D.C.’s Advisory Committee on Immunization Practices, before saying that his hand-picked replacements would review the U.S. childhood-immunization schedule.

An enormous amount of energy has gone into grossly misleading “debates” about vaccine safety and effectiveness. As anti-vaccine sentiment grows, it threatens global vaccine goals and makes all of us more vulnerable to preventable diseases. *Read Rivka Galchen’s report on the costs of vaccine skepticism: https://lnkd.in/gzg_3y8c*

.....

[AAP Stands Strong on Childhood Vaccines](#)

American Academy of Pediatrics

Video: 00:02:11 Transcript available at link above

Jun 20, 2025

At a time when there’s confusion in Washington, D.C., around vaccine recommendations, the American Academy of Pediatrics continues to do what it’s always done: use science to develop guidelines to improve the health of all children. For decades, the AAP has published its own childhood immunization schedule based on these guiding principles, and it will continue to do so. Families and pediatricians know they can trust the resources published by the AAP.

.....
.....

U.S. Research Funding

[Proposed cuts could have ‘catastrophic effect,’ 110 biomedical, health sciences industry](#)

An open letter from CEOs and board chairs concerned about the future

By 110 Biopharma Leaders [The authors and signatories are CEOs and board chairs of biomedical/health sciences companies; List at title link above - paywall]

June 27, 2025

As leaders of United States companies positioned in the biomedical/health sciences landscape, we are well aware that our companies are but one component of an expansive and interconnected scientific ecosystem requiring federal, industry, and academic partnership.

Government funding of research and industry work in the life sciences plays a critical role in this ecosystem, creating a cycle of innovation and economic growth that improves the health and well-being of the nation’s citizens and helps to ensure that the United States leads in critical areas such as therapeutic development, advanced biomanufacturing, AI-informed technologies, and more.

Given the currently proposed cuts to federal funding for scientific research, including extensive cuts to the National Institutes of Health and National Science Foundation in the fiscal year 2026 budget, **we believe it is imperative — and urgent — to articulate that federal funding for scientific research is essential to the sustainability of the biomedical industry,** maintaining the United States’ technological edge, and crucial for this country’s ability to protect and strengthen our economic and national security.

Damaging reductions in research funding provided to academic and federal scientists will immediately hurt the biotechnology sector in six key ways:

1. Elimination of many graduate student training programs and postdoctoral research positions will reduce the pipeline of highly trained scientists we rely on to perform the work within our companies.
2. Cancellation of federal grants and contracts that directly support companies (e.g., small business grants, service contracts, technology development contracts) will reduce our ability to develop innovative products.
3. Elimination of numerous subcontracts to our companies to perform services required for research (e.g., development of assays for understanding, diagnosing, and treating disease; supply of specialized research equipment; clinical trial support; etc.) will delay the introduction of transformative innovations to the American public.
4. Delays in basic and clinical research advances that create a pipeline for research and development at our companies.
5. Diminished resources for new spinoff/startup companies emerging directly from academic research.
6. Reductions in purchase orders for research supplies, reagents, personal protective equipment, etc., required for conducting scientific research will decrease revenues and slow growth.

We together state that a reduction in federal research funding on the scale currently contemplated for fiscal year 2026 will have a catastrophic effect on the advancement of biomedical and biotechnology capabilities in the United States. Continued and robust federal funding of scientific research is required to preserve the health of the U.S. scientific ecosystem, allowing the U.S. to continue to lead the world in the advancement of scientific innovation, knowledge, and health. The views expressed here are our own and not necessarily those of our companies.

.....

Malaria

Price of world's first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than \$5

:: Price reduction is commitment by Bharat Biotech, made possible through partnership with GSK and driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins

:: Bharat Biotech and GSK make this announcement as part of their pledges to Gavi replenishment process for 2026 - 2030

:: Through Gavi support, RTS,S expected to be rolled out in 12 endemic countries in Africa through routine immunisation programmes by end of 2025

Press release 25 June 2025, London UK and Hyderabad, India

Bharat Biotech International Limited (BBIL) and GSK plc (LSE/NYSE: GSK) today announce their commitment to Gavi, the Vaccine Alliance (Gavi), in the continued roll out of the world's first malaria vaccine. Bharat Biotech will be reducing the price of RTS,S, developed by GSK, PATH and partners, by more than half, to less than \$5 progressively by 2028. This price reduction is driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins. **The announcement forms part of pledges to Gavi for its next replenishment phase (Gavi 6.0, 2026-2030) by both companies...**

With Gavi's support, 12 endemic countries in Africa will have introduced RTS,S through routine immunisation programmes by the end of 2025. This has only been possible through the critical work that **GSK has undertaken with Bharat Biotech, PATH, together with the WHO, implementing countries, MedAccess and Gavi**, to help deliver access to life-saving malaria prevention for children in endemic countries in Africa....

.....
.....

Health Research – Priority Setting

WHO guidance on the ethics of health research priority setting

23 June 2025 | Publication

PDF: <https://iris.who.int/bitstream/handle/10665/381711/9789240110953-eng.pdf?sequence=1>

Overview

The resources available for health research at any given time – including money but also time, infrastructure and personnel – are scarce. Not every valuable research project can be carried out. Investing resources in one project takes resources away from others. This means that decisions must be made about which among the many possible valuable research projects should be conducted first. Health research priority setting is the process through which decisions or recommendations are made about what health research should be prioritized. It encompasses a range of activities that organizations may label “priority-setting exercises,” “strategic planning,” or “agenda setting.”

Since decisions about what health research is carried out are decisions about how to distribute scarce and very important potential benefits among different populations, such decisions are not merely technical. These decisions also incorporate value judgements—including concerning whose interests count and what constitutes a fair allocation of resources. This means that ethics is a fundamental element of research priority setting: to identifying the goals at which it aims, the way it is conducted, and who it involves.

This guidance aims to synthesize current good practice for incorporating ethics into health research priority setting. It is relevant to anyone making decisions about what research to support or conduct, including funders, policy makers, research institutions, health researchers, and patient groups...

.....
.....

COVID-19 Origin[s]

WHO Scientific advisory group issues report on origins of COVID-19

27 June 2025

News release, Geneva

The WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), a panel of 27 independent, international, multidisciplinary experts, today published its report on the origins of SARS-CoV-2, the virus responsible for the COVID-19 pandemic.

SAGO has advanced the understanding of the origins of COVID-19, but as they say in their report, much of the information needed to evaluate fully all hypotheses has not been provided.

“I thank each of the 27 members of SAGO for dedicating their time and expertise to this very important scientific undertaking over more than three years,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. **“As things stand, all hypotheses must remain on the table, including zoonotic spillover and lab leak.** We continue to appeal to China and any other country that has information about the origins of COVID-19 to share that information openly, in the interests of protecting the world from future pandemics.”

In its report, SAGO considered available evidence for the main hypotheses for the origins of COVID-19 and **concluded that “the weight of available evidence...suggests zoonotic spillover...either directly from bats or through an intermediate host.”**

WHO requested that China share hundreds of genetic sequences from individuals with COVID-19 early in the pandemic, more detailed information about the animals sold at markets in Wuhan, and information on work done and biosafety conditions at laboratories in Wuhan. To date, China has not shared this information either with SAGO or WHO.

SAGO published its initial findings and recommendations in a report on 9 June 2022. Today's report updates that evaluation based on peer-reviewed papers and reviews, as well as available unpublished information and field studies, interviews, and other reports including audit findings, government reports and intelligence reports. SAGO convened in various formats 52 times, conducted briefings with researchers, academics, journalists, and others.

"As the report says, this is not solely a scientific endeavour, it is a moral and ethical imperative," said Dr Marietjie Venter, Chair of the group and Distinguished Professor and One Health Research Chair in Vaccines and Surveillance for Emerging viral threats at the University of the Witwatersrand, South Africa. "Understanding the origins of SARS-CoV-2 and how it sparked a pandemic is needed to help prevent future pandemics, save lives and livelihoods, and reduce global suffering."...

The work to understand the origins of SARS-CoV-2 remains unfinished. WHO welcomes any further evidence on the origins of COVID-19, and SAGO remains committed to reviewing any new information should it become available.

.....
.....

Polio – PHEIC

Polio this week – 25 June 2025

Headlines [Selected]

:: "The Audacity to Start the job; the Tenacity to Finish it" – PolioPlus takes centre stage at Rotary Convention in Calgary

As tens of thousands of Rotarians from around the world gathered at the Rotary International Convention in Calgary, Canada, this weekend, Rotary and the Gates Foundation [announced](#) an extended partnership to end polio for good, which will see an injection of nearly half a billion dollars into the effort.

...

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: one WPV1 case and seven WPV1-positive environmental samples
- Benin: one cVDPV2 case
- Chad: one cVDPV2-positive environmental sample
- Djibouti: one cVDPV1-positive environmental sample and two cVDPV2-positive environmental samples
- Ethiopia: one cVDPV2 case
- Tanzania: one cVDPV2-positive environmental sample
- Yemen: one cVDPV2 case

.....
.....

mPox – PHEIC

Multi-country outbreak of mpox, External situation report #54 - 27 June 2025

KEY FIGURES			
Area	Number of reported confirmed cases	Number of deaths among confirmed cases	Number of reporting countries
Global (1 Jan – 31 May 2025)*	24 672	82	75
Key countries (01 Jan – 22 June 2025)			
Democratic Republic of the Congo	12 208	22	-
Uganda	5636	31	-
Sierra Leone	4294	28	-
Burundi	1079	0	-

* Most recent global surveillance data available.

Highlights

- In May 2025, a total of 6823 confirmed mpox cases and 16 deaths (Case Fatality Ratio: 0.2%) were reported from 49 countries across all WHO regions.
- The majority of mpox cases continue to be reported from the WHO African Region, with 18 countries currently experiencing active ongoing transmission.
- Since the last report, Ethiopia and Italy have reported their first cases of mpox due to clade Ib monkeypox virus (MPXV). In addition, North Macedonia, the Republic of the Congo, and Togo have reported their first cases of mpox clade IIb MPXV. Albania has reported its first mpox case, and genomic sequencing analysis is underway to determine the clade.
- Community transmission of clade Ib MPXV remains limited to countries in Central and East Africa.
- In Sierra Leone, the epidemic trend is consistently declining, although recent data should be interpreted with caution due to reporting delays.
- Eleven African countries have received mpox vaccines, of which seven have started mpox vaccination. More than 731 000 doses of the MVA-BN vaccine have been administered to date.
- WHO has updated its guideline on clinical management and infection prevention and control for mpox.
- The WHO Director-General determined that the ongoing upsurge of mpox continues to constitute a public health emergency of international concern (PHEIC), following the fourth meeting of the International Health Regulations (IHR) Emergency Committee on 5 June 2025

[Excerpt]

Vaccines

- WHO continues to provide guidance and technical support to countries on mpox targeted vaccination strategies with focus on geographic areas with the highest number of new cases and in those, people at high risk of exposure based on local epidemiology.
- To date, 2 952 280 vaccine doses have been delivered to eleven countries of which 1 550 000 doses of LC16m8 vaccine from Japan to the Democratic Republic of the Congo in January and May 2025.
- Mpox vaccination activities have started in seven countries with MVA-BN (the Central African Republic, Democratic Republic of the Congo, Liberia, Nigeria, Rwanda, Sierra Leone, and Uganda), several of which are implementing a single-dose strategy targeting population groups at high risk of exposure. More than 731 000 MVA-BN vaccine doses have been administered, of which more than 80% in DRC. Other countries are developing their national mpox vaccination plans.
- In the current context of limited MVA-BN vaccine supply due to funding constraints and in alignment with previous WHO recommendations, WHO released an FAQ on use of intradermal

fractional dosing of mpox MVA-BN vaccine with the aim to support countries in their considerations. The use of dose-sparing options was also discussed as part of the AFRO Regional Immunization Technical Advisory Group (RITAG) meeting that took place on 26 June 2025.

- WHO recently published interim guidance on the use of LC16m8 vaccine and training modules with the aim to support the Democratic Republic of the Congo in planning the deployment of LC16m8 vaccine doses. A pilot with LC16m8 vaccine has started in one health zone in Kinshasa including active follow-up of vaccinees for Adverse Events Following Immunization (AEFI monitoring). Around 100 doses have been administered to date, and additional LC16m8 vaccination sessions are being planned.
- WHO, UNICEF and the International Federation of Red Cross and Red Crescent Societies (IFRC) have published guidance on how to achieve and sustain high uptake of mpox vaccination in outbreak settings.
- The AAM partners continue to work together to ensure countries receive guidance to get operational funds for implementation of the national vaccination plans.
- The Coalition for Epidemic Preparedness Interventions is holding a technical consultation on correlates of protection for mpox vaccines on 26 - 27 June 2025 in order to chart pathways for regulatory consideration of vaccine candidates.

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

WHO & Regional Offices [to 28 June 2025]

<https://www.who.int/news>

Selected News/Announcements/Statements

[WHO Scientific advisory group issues report on origins of COVID-19](#)

27 June 2025

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 28 June 2025

[WHO supporting Guinea restore vaccine capacity after fire damage](#)

:: 24 June 2025

[Expanding access to sexual and reproductive health services in Ethiopia](#)

WHO Region of the Americas PAHO

:: 27 Jun 2025

[Strategic Decisions for Regional Health Mark Close of PAHO's 176th Executive Committee Meeting](#)

Washington, D.C., June 27, 2025 (PAHO) – After four days of deliberations, the 176th session of the Pan American Health Organization (PAHO) Executive Committee concluded yesterday. Representatives

from nine Member States adopted fundamental decisions for the future of public health in the region. These decisions will serve as the basis for...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 26 June 2025 *Media release*

[New data: noncommunicable diseases cause 1.8 million avoidable deaths and cost US\\$ 514 billion every year, reveals new WHO/Europe report](#)

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

[Multi-country outbreak of mpox, External situation report #54 - 27 June 2025](#)

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

[Reporting trends and seasonality in the World Health Organization's Disease Outbreak News \(DONs\) across 1996-2023](#)

Kellerine Quah, Jingtong Jin, Charlotte Christiane Hammer

PREPRINT - medRxiv 2025.06.17.25329744; doi: <https://doi.org/10.1101/2025.06.17.25329744>

Abstract

The Disease Outbreak News (DONs), which are published by the World Health Organization, are used in outbreak surveillance, management and research as official reports of disease outbreaks worldwide. This study analyzed datasets of the DON created by Carlson et al. (2023) and Weets et al. (2025) to understand reporting behavior in DONs published across 1996-2023. Time series analysis was conducted by disease transmission group and geography. Interrupted time series analyses were conducted to investigate changes in reporting behavior before and after the 2003 SARS-CoV-1 outbreak, and before and during the COVID-19 pandemic. We observed an annual, 12-month seasonality in reporting across all DONs. By disease transmission group, Airborne and Droplet transmission-related DONs and Vector-borne transmission-related DONs exhibited 12-month seasonality in reporting. Faecal-oral and FWB transmission-related DONs exhibited 9-month seasonality in reporting. Findings from our interrupted time series analyses revealed that during the COVID-19 pandemic, reporting across all DONs decreased, with a step-change difference of -3.73 reports at baseline comparing negative binomial regression models before and during the pandemic. In addition, after the 2003 SARS-CoV-1 outbreak, reporting of Airborne and Droplet transmission-related DONs increased, with a step-change difference of 3.77 reports at baseline comparing negative binomial regression models before and after the outbreak. As a collection of press releases which are selectively published by the WHO, the DON is not a complete representation of global disease outbreaks, and researchers should be aware of these reporting patterns and biases when using the DONs in outbreak surveillance and global health research.

.....

Weekly Epidemiological Record

Vol. 100, No. 26, pp. 251–264 27 June 2025

<https://www.who.int/publications/journals/weekly-epidemiological-record>

:: Estimated current and future incidence of congenital rubella syndrome in 19 countries with and without introduction of rubella vaccine, 2019–2025

.....

New WHO Publications

<https://www.who.int/publications>

Selected

23 June 2025

[**Development and implementation of national action plans for infection prevention and control: practical...**](#)

23 June 2025

[**The ethics of health research priority setting**](#)

23 June 2025

[**WHO guidance on the ethics of health research priority setting**](#)

23 June 2025

[**Considerations for use of avian influenza A\(H5\) vaccines during the interpandemic and emergence periods:...**](#)

19 June 2025

[**Tracking governance and administration expenditure under the System of Health**](#)

.....

.....

Editor's Note:

As a service to readers, we employ bolded red text below to identify potentially problematic content and observations added by the Editor.

USA – HHS, FDA, CDC+

White House

Presidential Actions – Executive Orders

No new digest content identified.

HHS

News

News Releases

No new digest content identified.

NIH [to 28 June 2025]

<http://www.nih.gov/>

News Releases

No new digest content identified.

FDA

Press Announcements

No new digest content identified.

CDC/ACIP [to 28 June 2025]

<http://www.cdc.gov/media/index.html>

Latest News

CDC's Advisory Committee on Immunization Concludes Meeting with Joint Statement

ATLANTA—JUNE 26, 2025

ACIP Meetings [to 28 June 2025]

Next ACIP Meetings

:: August/September (dates TBD)

:: October 22-23

MMWR Weekly

<https://www.cdc.gov/mmwr/index2025.html>

June 26, 2025 / No. 23

PDF of this issue

FDA VRBPAC

Advisory Committee Calendar

No new meetings scheduled.

National Vaccine Program

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

Next ACCV Meeting - TBD

We are rescheduling the ACCV Meetings originally planned for Wednesday, January 29, 2025, and Thursday, January 30, 2025. Once the new dates are confirmed, information will be available here on the ACCV website and announced in the Federal Register.

.....
.....

Europe

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

[Webinar - The epidemiological situation of autochthonous cases of Aedes-borne diseases in Europe and introduction of the public health guidance](#)

27 Jun 2025

Surveillance and monitoring

[Communicable disease threats report, 21-27 June 2025, week 26](#)

27 Jun 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 June 2025 and includes updates on respiratory virus epidemiology in the EU/EEA, influenza A(H5N1), avian influenza (A(H10N3); A(H9N2)), mass gathering monitoring (EuroPride 2025), autochthonous chikungunya virus disease, Crimean-Congo haemorrhagic fever, West Nile virus infection, and poliomyelitis.

Surveillance and monitoring

Seasonal surveillance of chikungunya virus disease in the EU/EEA

27 Jun 2025

This report gives an overview of the countries and areas where chikungunya virus disease cases – and their corresponding case numbers - have been reported to the European surveillance portal for infectious diseases (EpiPulse).

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

No new digest content identified.

.....
.....

Africa CDC [to 28 June 2025]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Press Releases

Africa Unites to Take Stock of Disease Burden and Financial Needs towards NTDs Elimination

.....

China CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 28 June 2025]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 28 June 2025]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-06-27 / No. 26

[PDF of this issue](#)

- [Commentary: From Global Consensus to Local Action: China's Strategic Response to Emerging Drug Use Trends](#)

- [Vital Surveillances: Epidemiological Characteristics and Spatiotemporal Cluster Analysis of Scrub Typhus — China, 2006–2023](#)
- [Preplanned Studies: Drug Resistance of Imported *P. falciparum* and *P. vivax* Isolates — China, 2021–2023](#)
- [Reviews: Tick-Borne Infectious Diseases in China, 2003–2023](#)

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)
 :: [WHO](#)
 :: [Organization Announcements](#)
 :: [Journal Watch](#)
 :: [Pre-Print Servers](#)

.....

Organization Announcements

Paul G. Allen Frontiers Group [to 28 June 2025]

<https://alleninstitute.org/news-press/>

Recent News

No new digest content identified.

BMGF - Gates Foundation [to 28 June 2025]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

Press release Jun 26, 2025

[**World Leaders Recommit to Immunisation Amid Global Funding Shortfall**](#)

Statement Jun 25, 2025

[**Mark Suzman's Statement on Outcome of Gavi Pledging Event**](#)

Press release Jun 24, 2025

[**Child Deaths Will Rise if Funding for Lifesaving Vaccine Program Falters**](#)

CARB-X [to 28 June 2025]

<https://carb-x.org/>

News

No new digest content identified.

Chan Zuckerberg Initiative [to 28 June 2025]

<https://chanzuckerberg.com/newsroom/>

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 28 June 2025]

<http://cepi.net/>

CEPI News, Blog

News

News

[CEPI appoints Executive Director of People and Organisation](#)

Claire Hoang Sperandio will join CEPI in September.

26 Jun 2025

CIDRAP – Vaccine Inventory Project

<https://www.cidrap.umn.edu/vaccine-integrity-project>

News, Viewpoints

[CDC's upcoming vaccine advisory meeting set up to sow distrust in vaccines \(June 23, 2025\)](#)

This week's meeting of the Advisory Committee on Immunization Practices (ACIP) is likely to mark its end—for now—as a vaccine advisory body...

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 28 June 2025]

<https://cioms.ch/>

News; Publications; Events

[CIOMS Glossary of ICH Terms & Definitions](#)

A glossary of ICH terms and definitions has been compiled by CIOMS from across ICH Guidelines. For information on this helpful CIOMS initiative, please visit the [CIOMS website](#), where the glossary is freely available for download, providing a useful resource for both CIOMS and ICH Stakeholders and Working Groups.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 28 June 2025]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [to 28 June 2025]

<https://dndi.org/press/press-releases/>

Press Releases

Publications 27 Jun 2025

[2024 DNDi Financial Report](#)

Duke Global Health Innovation Center [to 28 June 2025]

<https://dukeghic.org/>

News

[Mpox Transparency and Accountability for the Global Response](#)

June 27, 2025

Welcome to the sixteenth issue of our report, "Mpox: Transparency and Accountability for the Global Response."

EDCTP [to 28 June 2025]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 28 June 2025]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 28 June 2025]

<http://www.euvaccine.eu/>

Latest News, Events

ShigaPlexIM: SUNSHINE trial vaccination started at the Centre for Infectious Disease Research in Zambia

The SUNSHINE trial has now proceeded to the start of vaccination of participants living in Shigella endemic setting at the Centre for Infectious Disease Research in Zambia (CIDRZ).

Fondation Merieux [to 28 June 2025]

<http://www.fondation-merieux.org/>

News, Events

Événement co-organisé par la Fondation Mérieux

3ème édition du cours avancé sur l'épidémiologie dans les situations d'urgence complexes

7-11 juillet 2025 - Centre des Pensières, Veyrier-du-Lac (France)

Gates Medical Research Institute [to 28 June 2025]

<https://www.gatesmri.org/news>

The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

News: Articles and Publications

No new digest content identified.

Gavi [to 28 June 2025]

<https://www.gavi.org/>

Press Releases

25 June 2025

World leaders recommit to immunisation amid global funding shortfall

:: The Global Summit: Health & Prosperity through Immunisation sees a record number of donors pledge towards Gavi, the Vaccine Alliance, securing more than US\$ 9 billion towards a target budget of US\$ 11.9 billion for its next strategic period (2026–2030)

:: Additional commitments were made, including an unprecedented US\$ 4.5 billion in complementary financing from development finance institutions in support of country systems and accelerated access

to vaccines, cost savings of up to US\$ 200 million from manufacturers, and more than US\$ 149 million in private sector partnerships focused on immunisation delivery

:: With some donors unable to pledge support at the Summit due to their domestic budgetary cycles, Gavi will continue to work with its donors to ensure its next strategic period is fully funded, as a shortfall will leave millions of children unvaccinated and increase health security risks

25 June 2025

Gavi statement on the global health architecture

25 June 2025

Statement

Gavi statement in response to comments made by the United States Secretary for Health and Human Services at the Global Summit: Health and Prosperity through Immunisation, Brussels, 25 June 2025.

GE2P2 Global Foundation [to 28 June 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – May 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 25 May 2025](#)

:: [Genomics :: Governance, Ethics, Policy, Practice – A Monthly Digest – May 2025](#)

GHIT Fund [to 28 June 2025]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 28 June 2025]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 28 June 2025]

<https://www.glopid-r.org/>

Website not responding at inquiry.

Hilleman Laboratories [to 28 June 2025]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 28 June 2025]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 28 June 2025]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 28 June 2025]

<https://www.iavi.org/>

Press Releases, Features

No new digest content identified.

INSERM [to 28 June 2025]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 28 June 2025]

<https://www.ich.org/>

News/Pubs/Press Releases [Selected]

27 June 2025

[ICH M4Q\(R2\) Step 2 Presentation Now Available on the ICH Website](#)

In follow up to the publication of the ICH M4Q(R2) draft revised Guideline in May 2025, the EWG has also prepared a Step 2 informational presentation.

25 June 2025

[ICH E20 Draft Guideline is Available Now on the ICH Website](#)

The ICH E20 draft Guideline on “Adaptive Design for Clinical Trials” has reached Step 2b of the ICH Process on 25 June 2025 and entered the Step 3 public consultation period.

Ongoing Public Consultations	
> M11 EWG	Clinical electronic Structured Harmonised Protocol (CeSHarP)
> M13B EWG	Bioequivalence for Immediate-Release Solid Oral Dosage Forms
> Q1 EWG	Stability Testing of Drug Substances and Drug Products
> M4Q(R2) EWG	Revision of M4Q(R1)
> E21 EWG	Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials

<https://www.ich.org/page/public-consultations>

ICRC [to 28 June 2025]

<https://www.icrc.org/en/news>

Latest press releases and statements [Selected]

ICRC president: When the rules of war are applied selectively, they lose their protective power

Statement 27-06-2025

Myanmar: Rebuilding lives shattered by earthquake and armed conflict

News release 27-06-2025

Ethiopia: Tens of thousands of people receive seeds and fertilizers in conflict-affected regions

News release 24-06-2025

IFFIm [to 28 June 2025]

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 28 June 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press releases

IFRC mourns the killing of another Palestine Red Crescent colleague in Gaza

27/06/2025 | Press release

IPPS - International Pandemic Preparedness Secretariat [to 28 June 2025]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

Institut Pasteur [to 28 June 2025]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 28 June 2025]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

blog

27 June 2025 - 20 min read

To serve their vital role in the research ecosystem, publishers should follow these eight principles

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

19th International Congress of Immunology

Vienna, August 17-22, 2025.

IVAC [to 28 June 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

U.S. Measles Tracker

Tracking Measles Cases in the U.S.

Updated June 27, 2025

IVI [to 28 June 2025]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 28 June 2025]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 28 June 2025]

<http://www.msf.org/>

Latest [Selected Announcements]

Gaza-Israel war

Deadly Israeli-US supply distribution scheme in Gaza must be dismantled ...

Press Release 27 Jun 2025

Democratic Republic of Congo

MSF responds to cholera outbreak following gold discovery in Lomera, Sout...

Project Update 26 Jun 2025

Conflict in Sudan

Sudanese refugees in Chad are safe from bombs but struggling to survive

Project Update 25 Jun 2025

Libya

MSF remains ready to resume medical activities in Libya

Press Release 24 Jun 2025

National Academy of Medicine - USA [to 28 June 2025]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 28 June 2025]

<https://www.nationalacademies.org/newsroom>

News

No new digest content identified.

PATH [to 28 June 2025]

<https://www.path.org/media-center/>

Newsroom [Selected]

No new digest content identified.

Sabin Vaccine Institute [to 28 June 2025]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 28 June 2025]

<http://www.unaids.org/en>

News, Stories, Updates

Press Release

'We do not give up! UNAIDS will continue to stand with governments and communities' was the message at UNAIDS' 56th board meeting

GENEVA, 27 June 2025—UNAIDS 56th Programme Coordinating Board (PCB) meeting concluded in Geneva, Switzerland this week at an unprecedented moment in the AIDS response with sudden and drastic cuts to HIV funding by international donors.

"We are seeing a massive interruption in international HIV financing which has created a systemic shock to the global HIV response, triggering huge disruptions to HIV treatment and prevention programmes around the world," said Winnie Byanyima, Executive Director of UNAIDS.

"However, our Joint Programme was created in crisis—it is in our DNA to face crisis and to fight our way out of crisis. We do not give up—we continue to stand with governments and communities as they commit to finish the fight to end AIDS."

During the meeting board members endorsed UNAIDS' new operating model based on the recommendations of the High-level panel for a resilient and fit-for-purpose UNAIDS and the direction of travel of UN80. The operating model underpins UNAIDS' transformation, including the restructuring exercise currently underway for the UNAIDS Secretariat.

Board members endorsed four core functions for the UNAIDS Secretariat: Leadership and advocacy (including for global resource mobilization); Convening and coordination focused on sustainability of the global HIV response; Accountability through data, targets, strategy; and Community engagement—which will guide UNAIDS' work going forward.

Board members, member states, civil society, communities, cosponsors and observers—all expressed solidarity with UNAIDS at this challenging juncture and board members showed their continued full confidence in the UNAIDS Joint Programme...

UNICEF [to 28 June 2025]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements [Selected]

"World is failing to protect children from the horrors of war"

UNICEF Director of Child Protection Sheema Sen Gupta's remarks at the UN Security Council Open Debate: 'Children and armed conflict: effective strategies to end and prevent grave violations against children.'
25 June 2025

Unitaid [to 28 June 2025]

<https://unitaid.org/>

News

News releases

[“We must rethink how we work”: New Unitaid report showcases how innovation and access strategies can support stronger country-led health systems](#)

23 June 2025

Vaccine Equity Cooperative [nee Initiative] [to 28 June 2025]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccine Confidence Project [to 28 June 2025]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 28 June 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

[Vaccine Update Newsletter June 2025](#)

[June/July 2025: Thimerosal in Multidose Vaccine Vials: Then and Now](#)

Dr. Paul Offit talks about the history of thimerosal in vaccines. You’ll also find resources related to COVID-19 vaccines, measles outbreaks, and the June ACIP meeting.

Wellcome Trust [to 28 June 2025]

<https://wellcome.org/news/all>

News. Opinion, Reports

News

[Researchers take first steps to creating synthetic human genomes](#)

26 June 2025 4-minute read

A team of UK-based scientists are developing technology to create the first synthetic human chromosome. The ability to write large genomes has the potential to transform our understanding of human health, opening opportunities to develop cell therapies, climate-resistant crops and more.

The Wistar Institute [to 28 June 2025]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

World Bank [to 28 June 2025]

<http://www.worldbank.org/en/news/all>

All News [Selected]

Extreme Poverty is Rising Fast in Economies Hit by Conflict, Instability

Development Setbacks Mount as Frequency of Conflict Surges to 25-Year High

WASHINGTON, June 27, 2025—Conflict and instability are taking a devastating toll on the 39 economies afflicted by them, driving up extreme poverty faster than anywhere else, intensifying acute hunger, and pushing several key development goals farther out of reach, according to the World Bank's first comprehensive assessment of their plight in the aftermath of COVID-19.

As conflicts have become more frequent and deadly in the 2020s, these economies are falling behind all other economies in key indicators of development, the analysis finds. Since 2020, their per capita GDP has shrunk by an average of 1.8% per year, while it has expanded by 2.9% in other developing economies. This year, 421 million people are struggling on less than \$3 a day in economies afflicted by conflict or instability—more than in the rest of the world combined. That number is projected to rise to 435 million, or nearly 60% of the world's extreme poor, by 2030...

WFPHA: World Federation of Public Health Associations [to 28 June 2025]

<https://www.wfpfa.org/>

Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 28 June 2025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

Groups Representing Patients, Healthcare Professionals and Pharmaceutical Industry Author New Principle on Use of AI In Healthcare

26.06.2025

Six leading international organizations representing patients, physicians, pharmacists, nurses, hospitals, and the pharmaceutical industry have today adopted the first joint ethical principle in the healthcare industry on the responsible use of health data and technology, including artificial intelligence.

The new principle joins the International Consensus Framework for Ethical Collaboration (ICF), a longstanding principles-based voluntary agreement that guides ethical collaboration across these major healthcare bodies, working together to deliver high quality care for patients...

World Organisation for Animal Health [OIE] [to 28 June 2025]

<https://www.oie.int/>

Press Releases, Statements

No new digest announcements identified.

.....
.....

ARM [Alliance for Regenerative Medicine] [to 28 June 2025]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest announcements identified.

BIO [to 28 June 2025]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 28 June 2025]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 28 June 2025]

<https://internationalbiotech.org/news/>

News

[The Importance of Global Cooperation and Resilient Biopharmaceutical Supply Chains](#)

[Undated]

For the future of innovation and, most importantly, for the benefit of patients and citizens globally the International Council of Biotechnology Associations (ICBA) calls for continued strengthening and expansion of trade, regulatory, and scientific partnerships with global partners. Only through robust global cooperation can we build a resilient, innovative, biopharmaceutical and biotechnology ecosystem that benefits citizens everywhere.

Read Full Statement: [ICBA Statement on Global Cooperation and Trade](#)

IFPMA [to 28 June 2025]

<https://ifpma.org/>

News, Statements [Selected]

Press release 26 Jun 2025

[Groups representing patients, healthcare professionals and pharmaceutical industry author new principle on use of AI in healthcare](#)

Statement 25 Jun 2025

[The pharmaceutical industry supports Gavi's high-level pledging meeting](#)

On 25 June 2025, Gavi, the Vaccine Alliance, is co-hosting the Global Summit: Health & Prosperity through Immunization in support of its next five-year strategic period, in partnership with the European Union and the Gates Foundation.

External study 24 Jun 2025

[Key access pathways and bottlenecks for medicines in LMICs](#)

Medicines and vaccines have transformed the way we prevent, treat, and cure diseases. Bringing these to people around the world requires more than scientific breakthroughs – it demands collaboration across the entire innovation and access pathway. From discovery and development to regulatory approval, supply, procurement and local delivery, each step plays a critical role in...

International Alliance of Patients' Organizations – IAPO [to 28 June 2025]

<https://www.iapo.org.uk/news>

Press and media [Selected]

New Principle for Ethical Collaboration in Health

26 June 2025

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 28 June 2025]

<http://www.phrma.org/>

Press Releases

June 27, 2025

PhRMA Statement on This Week's ACIP Meetings

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

Press Releases - No new digest announcements identified.

Bavarian Nordic

Latest News

June 26, 2025

Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women

:: First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.

:: The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable populations.

Bharat Biotech

Press Releases

Press release 25 June 2025, London UK and Hyderabad, India

Price of world's first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than \$5

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified.

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry.

CIGB

Latest News - No new digest announcements identified.

CinnaGen

Recent News - Website not responding at inquiry.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

25 June 2025

[Price of world's first malaria vaccine \(RTS,S\) for children in endemic countries to be reduced by more than half, to less than \\$5](#)

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases

[ACIP Recommends Use of Merck's ENFLONSIA™ \(clesrovimab-cfor\) for Prevention of Respiratory Syncytial Virus \(RSV\) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season](#)

June 26, 2025 1:39 pm ET

:: ENFLONSIA is the first and only RSV preventive option for administration to infants using the same dose regardless of weight

:: Ordering will begin in July, with shipments delivered before the start of the 2025-2026 RSV season

Moderna

Press Releases - No new digest announcements identified.

Nanogen

News - No new digest announcements identified.

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified.

Serum Institute

News & Announcements - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases

June 26, 2025

[Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus](#)

Vector State Research Centre of Virology and Biotechnology

Home - [Website not responding [404 error]]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 6: E393-477

<https://journalofethics.ama-assn.org/issue/embodiment-art-practice>

Issue Theme: Embodiment in Art Practice

[Reviewed earlier]

American Journal of Human Genetics

Jun 05, 2025 Volume 112 Issue 6 p1249-1496

<https://www.cell.com/ajhg/current>

[This month in The Journal](#)

Alyson B. Barnes, Sara B. Cullinan

Within the field of prenatal genetic diagnosis, there is ongoing debate about whether fetal genomic sequencing (GS) should be offered for all pregnancies or only when a genetic disorder is suspected. Currently, the International Society of Prenatal Diagnosis recommends exome sequencing (ES) only in the presence of sonographic abnormalities. However, many treatable genetic disorders do not present with ultrasound abnormalities. In fact, recent studies have found that 0.6%–2.7% of sonographically normal fetuses harbor pathogenic or likely pathogenic variants expected to cause genetic disease, making a case for offering fetal GS to all pregnant individuals.

[Reviewed earlier]

American Journal of Infection Control

June 2025 Volume 53 Issue 6 p669-746

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

May 2025 Volume 68 Issue 5 p859-1050

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

June 2025 115(6)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 112 (2025): Issue 6 (Jun 2025)

<https://www.ajtmh.org/view/journals/tpmd/112/6/tpmd.112.issue-6.xml>

[Reviewed earlier]

Annals of Internal Medicine

June 2025 Volume 178, Issue 6

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 344 July 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/344/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 28 June 2025)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 28 June 2025)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 28 June 2025)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 28 June 2025)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 28 June 2025)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 28 June 2025)

No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 28 June 2025)

No new digest content identified]

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 28 June 2025)

[No new digest content identified]

BMJ Evidence-Based Medicine

June 2025 - Volume 30 - 3

<https://ebm.bmj.com/content/30/3>

[Reviewed earlier]

BMJ Global Health

June 2025 - Volume 10 - 6

<https://gh.bmj.com/content/10/6>

[Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - May 2025

<https://thebulletin.org/magazine/2025-03/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 103, Number 6, June 2025, 349-412

<https://www.who.int/publications/journals/bulletin/>

[Reviewed earlier]

Cell

Jun 12, 2025 Volume 188 Issue 12 p3097-3366

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

Cell and Gene Therapy Insights

May 2025 Issue Volume 11 Issue 4

<https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4>

[Reviewed earlier]

Child Care, Health and Development

Volume 51, Issue 4 July 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 118, Issue 1 Pages: 1-271 July 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

White Paper

ICH M12 Drug Interaction Studies: Summary of the Efforts to Achieve Global Convergence

Kellie Reynolds, Xinning Yang, Sheila Annie Peters, Vikram Sinha, Helen Heymann, Luiza Novaes Borges, Heidi J. Einolf, Shujun Fu, Motohiro Hoshino, Li Li, Elin Lindhagen, So Miyoshi, Katsuhiko Mizuno, Venkatesh Pilla Reddy, Matthias S. Roost, Ryota Shigemi, Xiaolu Tao, Meng-Syuan Yang, Sylvia Zhao, Carolien Versantvoort, Akihiro Ishiguro, Rajanikanth Madabushi

Pages: 33-44

First Published: 19 March 2025

Clinical Therapeutics

June 2025 Volume 47 Issue 6 p403-462

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 22 Issue 3, June 2025

<https://journals.sagepub.com/toc/ctja/22/3>

Articles

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 28 June 2025]

[No new digest content identified]

Contemporary Clinical Trials

Volume 153 June 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/153/suppl/C>

[New issue; No digest content identified]

The CRISPR Journal

Volume 8, Issue 3 / June 2025

<https://www.liebertpub.com/toc/crispr/8/3>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 3 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

June 2025 - Volume 38 - Issue 3

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 28 June 2025]

[No new digest content identified]

Cytotherapy

May 2025 Volume 27 Issue 5 p565-670

<https://www.isct-cytotherapy.org/current>

[Reviewed earlier]

Developing World Bioethics

Volume 25, Issue 2 Pages: 81-163 June 2025

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 35, Issue 4, 2025

<https://www.tandfonline.com/toc/cdip20/35/4?nav=tocList>

[Reviewed earlier]

Development Policy Review

Volume 43, Issue 4 July 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 49, Issue 3 July 2025

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

eBioMedicine

Volume 115 May 2025

<https://www.sciencedirect.com/journal/ebiomedicine/vol/115/suppl/C>

[Reviewed earlier]

EMBO Reports

Volume 26 Issue 1027 May 2025

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 5—May 2025

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 51 June 2025

<https://www.sciencedirect.com/journal/epidemics/vol/51/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 3, Pages: 1-45, May–June 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>

Undue inducement :: Deception in research

[Reviewed earlier]

Ethics & International Affairs

Volume 38 - Issue 4 - Winter 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 2, April 2025

<https://academic.oup.com/eurpub/issue/35/2>

[Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

May/June 2025 Volume 104, Number 3

<https://www.foreignaffairs.com/issues/2025/104/3>

[Reviewed earlier]

Forum for Development Studies

Volume 52, 2025 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities

[Reviewed earlier]

Frontiers in Genetics

<https://www.frontiersin.org/journals/genetics>

[Accessed 28 June 2025]

Editorial

Accepted on 25 Jun 2025

[Recent Advances in Genomics and Oncogenomics for Personalised Medicine](#)

Sulev Kõks

Original Research

Accepted on 24 Jun 2025

[Advancing Artificial Intelligence Ethics in Health and Genomics: Lessons from a Public Survey in South Korea](#)

JUNG IM LEE, Wonhoo Yoo, Hannah Kim

Frontiers in Genome Editing

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 28 June 2025]

[No new digest content identified]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 28 June 2025]

Perspective

Accepted on 27 Jun 2025

[Beyond Human Limits: The Ethical, Social, and Regulatory Implications of Human Enhancement](#)

Chiara Gerardi, Christodoulos Xinaris

Systematic Review

Accepted on 26 Jun 2025

[Bibliometric Analysis and Visualization Mapping of Herpes Zoster Vaccine Publications from 1999 to 2024](#)

Wenli Gao, et al.

Gene Therapy – Nature

Volume 32 Issue 3, May 2025

<https://www.nature.com/gt/volumes/32/issues/3>

[Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 6 June 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 28 June 2025]

Editorial

[Financial assistance programs for genetic testing: Effective, ethical, and sustainable pathways to improving access disparities?](#)

Emily Hammad Mrig, Kathryn A. Phillips, Mark Schlesinger

Article 101417

Global Health Action

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 28 June 2025]

[No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 28 June 2025]

[No new digest content identified]

Health and Human Rights

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

Special Section: Distress Migration and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 20 - Issue 1 - January 2025

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 5 June 2025

<https://academic.oup.com/heapol/issue/40/5>

[New issue; No digest content identified]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 28 June 2025]

[No new digest content identified]

Human Gene Therapy

Volume 36, Issue 11-12 / June 2025
<https://www.liebertpub.com/toc/hum/36/11-12>
[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 21 Issue 1, 2025
<https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList>
Selected Content
[Reviewed earlier]

Immunity

Jun 10, 2025 Volume 58 Issue 6 p1361-1614
<https://www.cell.com/immunity/current>
Articles
[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>
[Accessed 28 June 2025]
[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content/>
[Accessed 28 June 2025]
[No new digest content identified]

International Health

Volume 17, Issue 3, May 2025
<https://academic.oup.com/inthealth/issue/17/3>
[Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 2 (Dec 2024)
<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 5 (2025): May 2025
<https://www.ijcmph.com/index.php/ijcmph/issue/view/124>

[Reviewed earlier]

International Journal of Epidemiology

Volume 54, Issue 2, April 2025

<https://academic.oup.com/ije/issue/54/2>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18 Issue 1 2025

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/18/iss/1>

Table of contents

[Reviewed earlier]

JAMA

June 24, 2025, Vol 333, No. 24, Pages 2125-2216

<https://jamanetwork.com/journals/jama/currentissue>

Original Investigation

Modeling Reemergence of Vaccine-Eliminated Infectious Diseases Under Declining Vaccination in the US

Mathew V. Kiang, ScD; Kate M. Bubar, PhD; Yvonne Maldonado, MD; et al.

has active quiz

JAMA. 2025;333(24):2176-2187. doi:10.1001/jama.2025.6495

This study estimates the number of cases and complications in the US under scenarios of declining childhood vaccination for measles, rubella, poliomyelitis, and diphtheria.

Key Points

Question How will declining childhood vaccination rates affect the risk of outbreaks and reemergence of previously eliminated infectious diseases in the US?

Findings At current state-level vaccination rates, measles may become endemic again; increasing vaccine coverage would prevent this. Under a 50% decline in childhood vaccination in the US, the simulation model predicted 51.2 million measles cases over a 25-year period, 9.9 million rubella cases, 4.3 million poliomyelitis cases, 197 diphtheria cases, 10.3 million hospitalizations, and 159 200 deaths.

Meaning Childhood vaccination at a high coverage level is needed to prevent resurgence of vaccine-preventable infectious diseases and their infection-related complications in the US.

Abstract

Importance Widespread childhood vaccination has eliminated many infectious diseases in the US. However, vaccination rates are declining, and there are ongoing policy debates to reduce the childhood vaccine schedule, which may risk reemergence of previously eliminated infectious diseases.

Objective To estimate the number of cases and complications in the US under scenarios of declining childhood vaccination for measles, rubella, poliomyelitis, and diphtheria.

Design, Setting, and Participants A simulation model was used to assess the importation and dynamic spread of vaccine-preventable infectious diseases across 50 US states and the District of Columbia. The model was parameterized with data on area-specific estimates for demography, population immunity, and infectious disease importation risk. The model evaluated scenarios with different vaccination rates over a 25-year period. Inputs for current childhood vaccination rates were based on 2004-2023 data.

Main Outcomes and Measures The primary outcomes were estimated cases of measles, rubella, poliomyelitis, and diphtheria in the US. The secondary outcomes were estimated rates of infection-related complications (postmeasles neurological sequelae, congenital rubella syndrome, paralytic poliomyelitis, hospitalization, and death) and the probability and timing for an infection to reestablish endemicity.

Results At current state-level vaccination rates, the simulation model predicts measles may reestablish endemicity (83% of simulations; mean time of 20.9 years) with an estimated 851 300 cases (95% uncertainty interval [UI], 381 300 to 1.3 million cases) over 25 years. Under a scenario with a 10% decline in measles-mumps-rubella (MMR) vaccination, the model estimates 11.1 million (95% UI, 10.1-12.1 million) cases of measles over 25 years, whereas the model estimates only 5800 cases (95% UI, 3100-19 400 cases) with a 5% increase in MMR vaccination. Other vaccine-preventable diseases are unlikely to reestablish endemicity under current levels of vaccination. If routine childhood vaccination declined by 50%, the model predicts 51.2 million (95% UI, 49.7-52.5 million) cases of measles over a 25-year period, 9.9 million (95% UI, 6.4-13.0 million) cases of rubella, 4.3 million cases (95% UI, 4 cases to 21.5 million cases) of poliomyelitis, and 197 cases (95% UI, 1-1000 cases) of diphtheria. Under this scenario, the model predicts 51 200 cases (95% UI, 49 600-52 600 cases) with postmeasles neurological sequelae, 10 700 cases (95% UI, 6700-14 600 cases) of congenital rubella syndrome, 5400 cases (95% UI, 0-26 300 cases) of paralytic poliomyelitis, 10.3 million hospitalizations (95% UI, 9.9-10.5 million hospitalizations), and 159 200 deaths (95% UI, 151 200-164 700 deaths). In this scenario, measles became endemic at 4.9 years (95% UI, 4.3-5.6 years) and rubella became endemic at 18.1 years (95% UI, 17.0-19.6 years), whereas poliovirus returned to endemic levels in about half of simulations (56%) at an estimated 19.6 years (95% UI, 14.0-24.7 years). There was large variation across the US population.

Conclusions and Relevance Based on estimates from this modeling study, declining childhood vaccination rates will increase the frequency and size of outbreaks of previously eliminated vaccine-preventable infections, eventually leading to their return to endemic levels. The timing and critical threshold for returning to endemicity will differ substantially by disease, with measles likely to be the first to return to endemic levels and may occur even under current vaccination levels without improved vaccine coverage and public health response. These findings support the need to continue routine childhood vaccination at high coverage to prevent resurgence of vaccine-preventable infectious diseases in the US.

Viewpoint

Health and Human Services Restructuring—Threats to the US Preventive Services Task Force and Health

Alex H. Krist, MD, MPH; Scott M. Strayer, MD, MPH; Lei Charlton, MD; et al.

JAMA. 2025;333(24):2141-2142. doi:10.1001/jama.2025.7016

This Viewpoint discusses restructuring of the USPSTF while ensuring that its functions are safeguarded to avoid destabilizing vital public health infrastructure.

Preserving Research Ethics Oversight Amid Decimation of the Research Enterprise

Holly Fernandez Lynch, JD, MBE; Ivy Tillman, EdD, CIP; Elyse I. Summers, JD; et al.

JAMA. 2025;333(24):2143-2144. doi:10.1001/jama.2025.6361

From the start of his second term, the Trump administration has launched several blows to the US research enterprise, including swaths of canceled grants, unprecedented workforce reductions at the US Department of Health and Human Services (HHS), and efforts to slash the overhead rates ("indirects") essential to supporting the infrastructure and administration needed to conduct research. Legal challenges are pending against each of these actions, but the impact on scientists and scientific progress is already devastating.

JAMA Insights

Communicating Medicine

Strategies for Communicating With Parents About Vaccines

Sean T. O'Leary, MD, MPH

has active quiz has audio

JAMA. 2025;333(24):2197-2198. doi:10.1001/jama.2025.4882

This JAMA Insights explores vaccine hesitancy among parents and offers effective communication strategies for clinicians to build trust, handle difficult conversations, and ultimately improve vaccine uptake.

[Podcast](#): Strategies for Talking With Parents About Vaccines

JAMA Health Forum

June 2025, Vol 6, No. 6

<https://jamanetwork.com/journals/jama-health-forum/issue>

[New issue; No digest content identified]

JAMA Pediatrics

June 2025, Vol 179, No. 6, Pages 587-688

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[New issue; No digest content identified]

JB1 Evidence Synthesis

June 2025 - Volume 23 - Issue 6

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

July 2025 Volume 77 Issue 1 p1-172

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 82 (2025)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Bioethical Inquiry

Volume 21, Issue 4 December 2024

<https://link.springer.com/journal/11673/volumes-and-issues/21-4>

[Reviewed earlier]

Journal of Community Health

Volume 50, Issue 3 June 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-3>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

Journal of Development Economics

Volume 176 September 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/176/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 20 Issue 1-2, February-April 2025

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

June 2025 - Volume 79 - 6

<https://jech.bmj.com/content/79/6>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 2 June 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

Special Issue: 20th Anniversary Forum

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 2, May 2025

<https://muse.jhu.edu/issue/54734>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 27, Issue 3 June 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-3>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 23, Issue 2 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 37, Issue 4 pages: 1-1053 May 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

June 2025 - Volume 51 - 6

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 12, Issue 1 (2025)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 282 July 2025

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/282/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1

<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>

[Reviewed earlier]

Journal of Public Health Management & Practice

July/August 2025 - Volume 31 - Issue 4

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 46, Issue 2 June 2025

<https://link.springer.com/journal/41271/volumes-and-issues/46-2>

[Reviewed earlier]

Journal of the Royal Society – Interface

June 2025 Volume 22 Issue 227

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 32, Issue 4, May 2025

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 99 • Number 4 • April 2025

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Jun 28, 2025 Volume 405 Number 10497 p2255-2354

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

The Lancet Child & Adolescent Health

Jun 2025 Volume 9 Number 6 p361-438, e14

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

May 2025 Volume 7 Number 5

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jun 2025 Volume 13 Number 6 e974-e1150

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Jun 2025 Volume 25 Number 6 p595-700, e316-e369

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Jun 2025 Volume 10 Number 6 e433-e536

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Jun 2025 Volume 13 Number 6 p473-568, e30-e32

<https://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 29, Issue 6 June 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-6>

[Inequality in Utilization of Maternal Healthcare Services in Low- and Middle-Income Countries: A Scoping Review of the Literature](#)

Farjana Misu, Dominic Gasbarro, Khurshid Alam

Review Paper Open access 03 June 2025 Pages: 741 - 766

Medical Decision Making (MDM)

Volume 45 Issue 5, July 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 103, Issue 2 Pages: 243-637 June 2025

<https://onlinelibrary.wiley.com/toc/14680009/current>

[New issue; No digest content identified]

Molecular Therapy

Jun 04, 2025 Volume 33 Issue 6 p2311-2950

<https://www.cell.com/molecular-therapy/current>

Reviewed earlier]

Nature

Volume 642 Issue 8069, 26 June 2025

<https://www.nature.com/nature/volumes/641/issues/8069>

Editorial 24 Jun 2025

[In the face of anti-science politics, silence is not without cost](#)

More scientific leaders need to speak out about anti-science agendas and threats to academic freedom across the world.

Nature Biotechnology

Volume 43 Issue 6, June 2025

<https://www.nature.com/nbt/volumes/43/issues/6>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 28 June 2025)

[Reviewed earlier]

Nature Genetics

Volume 57 Issue 6, June 2025

<https://www.nature.com/ng/volumes/57/issues/6>

[Reviewed earlier]

Nature Human Behaviour

Volume 9 Issue 6, June 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/6>

Research Briefings

'Top of queue' text messages increased COVID-19 vaccine uptake in England

Two nationwide randomized controlled trials in England with over 4 million participants found that text messages that highlighted that people had reached the 'top of the queue' increased COVID-19 vaccination rates. As a result, this 'top of queue' message was subsequently rolled out as the standard text reminder.

Research Briefing 16 Apr 2025

Nationwide demonstration of improved COVID-19 vaccination uptake through behavioural reminders

Two nationwide randomized controlled trials in England with over 4 million participants found that text messages highlighting that people had reached the 'top of the queue' increased COVID-19 vaccination rates.

Hannah Behrendt, Giulia Tagliaferri, Robert Scott

Article 09 Apr 2025

Nature Medicine

Volume 31 Issue 6, June 2025

<https://www.nature.com/nm/volumes/31/issues/6>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 6, June 2025

<https://www.nature.com/nrd/volumes/24/issues/6>

[Reviewed earlier]

Nature Reviews Genetics

Volume 26 Issue 6, June 2025

<https://www.nature.com/nrg/volumes/26/issues/6>

[Reviewed earlier]

Nature Reviews Immunology

Volume 25 Issue 6, June 2025

<https://www.nature.com/nri/volumes/25/issues/6>

World View 07 May 2025

[Reviewed earlier]

New England Journal of Medicine

Volume 392 No. 24 June 26, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

Sounding Board

An Evidence-Based Approach to Covid-19 Vaccination

V. Prasad and M.A. Makary

NEJM Evidence

Volume 4 No. 5 May 2025

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 28 June 2025]

[No new digest content identified]

Pediatrics

Volume 155, Issue 6 June 2025

<https://publications.aap.org/pediatrics/issue/155/5>

[Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 6 June 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-6>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 28 June 2025)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 28 June 2025)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 28 June 2025)

Change in confidence in public health entities among US adults between 2020–2024

Hannah Melchinger, Saad B. Omer, Aryn A. Malik

Research Article | published 26 Jun 2025 PLOS Global Public Health
<https://doi.org/10.1371/journal.pgph.0004747>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 28 June 2025)

[Antimicrobial resistance in Africa: A retrospective analysis of data from 14 countries, 2016–2019](#)

Gilbert Osen, Geetanjali Kapoor, Erta Kalanxhi, Timothée Ouassa, Edwin Shumba, Sehr Brar, Yewande Alimi, Manuel Moreira, Martin Matu, Abdourahmane Sow, Eili Klein, Pascale Ondo, Ramanan Laxminarayan, the MAAP Study Group

Research Article | published 24 Jun 2025 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1004638>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 28 June 2025)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 28 June 2025]

[No new digest content identified]

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 28 June 2025]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

June 24, 2025 vol. 122 no. 25

<https://www.pnas.org/toc/pnas/122/25>

[New issue; No digest content identified]

PNAS Nexus

Volume 4, Issue 5, May 2025

<https://academic.oup.com/pnasnexus/issue/4/5>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 40 - Issue 2 - April 2025

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 194 May 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/194/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

June 2025 Volume 292 Issue 2048

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 244 July 2025

<https://www.sciencedirect.com/journal/public-health/vol/244/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 18, Issue 1, April 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

Public Health Reports

Volume 140 Issue 1, January/February 2025

<https://journals.sagepub.com/toc/phrg/140/1>

[Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 7, June 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 21 Issue 2, April 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 28 June 2025]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health
(RPSP/PAJPH)**

<https://www.paho.org/journal/en>

Latest Articles

23 Jun 2025

[Evidence map of strategies for preventing and controlling Aedes aegypti infestation and related viral infections](#)

Review | English |

Risk Analysis

Volume 45, Issue 5 Pages: 969-1185 May 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 28 June 2025]

[No new digest content identified]

Royal Society Open Science

June 2025 Volume 12 Issue 6

<https://royalsocietypublishing.org/toc/rsos/current>

[Reviewed earlier]

Science

Volume 388| Issue 6754| 26 Jun 2025

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

Science and Engineering Ethics

Volume 31, Issue 3 June 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-3>

[Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 804| 25 Jun 2025

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 28 June 2025]

[No new digest content identified]

Social Science & Medicine

Volume 380 September 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/380/suppl/C>

[New issue; No digest content identified]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 28 June 2025]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 3 June 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-3>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 65 May–June 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/65/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 30, Issue 6 Pages: i-iv, 459-575 June 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue; No digest content identified]

Vaccine

Volume 60 11 July 2025

<https://www.sciencedirect.com/journal/vaccine/vol/60/suppl/C>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 28 June 2025]

Open Access Article

[Exploring Vaccine Hesitancy, Structural Barriers, and Trust in Vaccine Information Among Populations Living in the Rural Southern United States](#)

by Alice R. Richman, Abby J. Schwartz, Sarah B. Maness, Leslie Sanchez and Essie Torres

Vaccines 2025, 13(7), 699; <https://doi.org/10.3390/vaccines13070699> (registering DOI) - 27 Jun 2025

Abstract

Introduction: In the United States, vaccine hesitancy is higher among rural and racially and ethnically diverse communities, and messaging from trusted individuals may increase vaccine acceptance. The purpose of this study is to understand vaccine hesitancy, messaging from trusted individuals, and vaccine acceptance [...]

Open Access Review

[Progress and Recent Developments in HIV Vaccine Research](#)

by Iris Shim, Lily Rogowski and Vishwanath Venketaraman

Vaccines 2025, 13(7), 690; <https://doi.org/10.3390/vaccines13070690> - 26 Jun 2025

Abstract

Background: Human immunodeficiency virus (HIV) remains a global health challenge despite significant advancements in antiretroviral therapy and prevention strategies. Developing a safe and effective vaccine that protects people worldwide has been a major goal, yet the genetic variability and rapid mutation rate of [...]

Open Access Article

[Assessment of Oral Poliovirus Vaccine Viability and Titer at Delivery Points in Kinshasa, the Democratic Republic of the Congo: Implications for Cold Chain Management](#)

by Gracia Kashitu-Mujinga, Anguy Makaka-Mutondo, Meris Matondo-Kuamfumu, Fabrice Mambu-Mbika, Junior Bulabula-Penge, Trésor Kabeya-Mampuela, Frida Nkawa, Grace Wanet-Taye, Bibiche Nsunda-Makanzu, Pierre Nsele-Muntatu, Lusamba Kabamba, Antoine Nkuba-Ndaye, Aimé Mwana wa bene Cikomola, Elisabeth Mukamba-Musenga and Steve Ahuka-Mundeke

Vaccines 2025, 13(7), 680; <https://doi.org/10.3390/vaccines13070680> - 25 Jun 2025

Abstract

Background: Poliomyelitis is a vaccine-preventable disease, with oral poliomyelitis vaccines (OPVs) and injectable poliomyelitis vaccines. In the Democratic Republic of the Congo (DRC), circulating vaccine-derived polioviruses (VDPVs) persist due to intrinsic and extrinsic factors, including the quality of the cold chain, which may [...]

Open Access Systematic Review

[COVID-19 Vaccine Timing and Co-Administration with Influenza Vaccines in Canada: A Systematic Review with Comparative Insights from G7 Countries](#)

by Farah Al hashimi, Sherif Eneye Shuaib, Nicola Luigi Bragazzi, Shengyuan Chen and Jianhong Wu
Vaccines 2025, 13(7), 670; <https://doi.org/10.3390/vaccines13070670> - 21 Jun 2025

Abstract

Background/Objectives: Despite significant advancements in vaccine development and distribution, the optimal timing and integration of COVID-19 vaccination in Canada remain crucial to public health. As the SARS-CoV-2 virus continues to evolve, determining effective timing strategies for booster doses is necessary to sustain immunity, [..]

Value in Health

June 2025 Volume 28 Issue 6 p813-978

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 191 July 2025

<https://www.sciencedirect.com/journal/world-development/vol/191/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)
:: [Journal Watch](#)
:: [Pre-Print Servers](#)

.....
.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 28 June 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

[arXiv:2506.19056](#) [pdf, html, other]

Self-selection of Information and Belief Update: An Experiment on COVID-19 Vaccine Information Acquisition

[ChienHsun Lin](#), [Hans H. Tung](#)

Rational information acquisition theory predicts that people select the more informative information. Thus, people's beliefs will be more persuaded by the information they select. We test the prediction in a critical real-world context -- information about COVID-19 vaccines. We conducted an online experiment in Taiwan where the subjects selected information about COVID-19 vaccines, and then the subjects updated their beliefs about vaccine effectiveness and references to vaccines. As our design distinguishes different stages of the rational acquisition framework, it allows us to diagnose the underlying mechanism of the theory. Our empirical findings demonstrate evidence that people's information acquisition generally coheres with the rational theory framework predictions; that is, people choose information when the information is more likely to alter their decisions. We show that our subjects' beliefs change more when they see the information they select. We also find evidence of change in vaccine preferences and choices after they receive the information they select, which further suggests that the subjects follow the rational information acquisition framework.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 28 June 2025]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 28 June 2025]

Seasonal forcing and waning immunity drive the sub-annual periodicity of the COVID-19 epidemic

[Ilan N Rubin](#), [Mary Bushman](#), [Marc Lipsitch](#), [William P Hanage](#)

medRxiv 2025.03.05.25323464; doi: <https://doi.org/10.1101/2025.03.05.25323464> Revision

Dissecting age-stratified immunity to different dengue virus serotypes and Zika viruses among children in a highly endemic region in Sri Lanka

[Shyrra Tanussiya Ramu](#), [Madushika Dissanayake](#), [Chamini Kanatiwela-de Silva](#), [Naduni Dasanthi](#), [Amaya Gunaratne](#), [Saubhagya Danasekara](#), [Laksiri Gomes](#), [Chandima Jeewandara](#), [Nicole L. Achee](#), [John P. Grieco](#), [H. Asitha de Silva](#), [D. S Anoja F. Dheerasinghe](#), [Thomas W. Scott](#), [Amy C. Morrison](#), [Hasitha Aravinda Tissera](#), [Gathsaurie Neelika Malavige](#)

Projections of human papillomavirus (HPV) vaccination impact on non-cervical cancer outcomes among women in 117 low-income and middle-income countries: a modeling study

Aarushi Tuli, Mark Jit, Kaja Abbas, Allison Portnoy

medRxiv 2025.06.24.25330224; doi: <https://doi.org/10.1101/2025.06.24.25330224>

ABSTRACT

Introduction Human papillomavirus (HPV) is a leading cause of both cervical and non-cervical cancers, including anal, oropharyngeal, vaginal, and vulvar cancers. While most HPV vaccination impact assessments have focused on preventing cervical cancer among women, the broader benefits of vaccination against other HPV-attributable cancers in low- and middle-income countries (LMICs) remain less explored.

Methods We used a static cohort model to assess the potential health impact of bivalent HPV vaccination on HPV-attributable female non-cervical cancers in 117 LMICs from 2030 to 2100. The model incorporated country-specific data on cancer mortality, HPV type distribution, demographic projections, and vaccine coverage. Sensitivity analyses were performed to account for uncertainties in cancer incidence and mortality, HPV type distribution, and cancer stage distribution.

Results Our projections suggest that HPV vaccination could contribute to prevention of approximately 0.59 million cases of anal, 0.88 million oropharyngeal, 1.27 million vaginal, and 2.18 million vulvar cancers over the analytic period. In total, 3.0 million deaths from these non-cervical cancers could be averted by 2100. The African Region is expected to see the largest relative reductions in both cases and deaths, while the European region showed the smallest gains. By the end of the century, 58 countries are projected to reach at least a 25% reduction in anal cancer mortality, compared to just 25 countries for oropharyngeal cancer. These findings reflect substantial regional disparities in both burden and vaccination impact.

Conclusion HPV vaccination holds considerable promise in reducing the burden of non-cervical cancers among women in LMICs, especially in regions with high incidence and limited access to care.

Recognizing and harnessing these broader benefits can strengthen the public health case for scaling up vaccine access, implementing region-specific strategies, and investing in equitable healthcare systems to decrease global disparities.

Examining the Pervasiveness of the Impact of COVID-19 and Associated Lockdown Policies on Pneumococcal Conjugate Vaccine (PCV) Coverage

Ruoxuan Wang, Bryan N. Patenaude

medRxiv 2025.06.23.25330136; doi: <https://doi.org/10.1101/2025.06.23.25330136>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 28 June 2025]

[No new digest content identified]

*

*

*

*

Think Tanks

Brookings [to 28 June 2025]

<http://www.brookings.edu/>

Reports, Events

Research

Tracking regulatory changes in the second Trump administration

June 25, 2025

Center for Global Development [to 28 June 2025]

<https://www.cgdev.org/>

All Research

BRIEF

How Much, How Well: Development Finance Performance 2025

Sam Hughes et al.

June 26, 2025

This brief examines how the 40 most important development finance providers perform in terms of both the quantity and quality of their contributions. Although several major providers recently announced significant cuts to their finance that are not yet reflected in the data, our analysis establishes...

Chatham House [to 28 June 2025]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 28 June 2025]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 28 June 2025]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 28 June 2025]

https://www.kff.org/search/?post_type=press-release

Newsroom

U.S. Foreign Aid Freeze & Dissolution of USAID: Timeline of Events

June 26, 2025

Overview of President Trump's Executive Actions on Global Health

June 26, 2025

Global Health Funding Awards by State and Congressional District

June 24, 2025

McKinsey Global Institute [to 28 June 2025]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 28 June 2025]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 28 June 2025]

<https://www.pewresearch.org/>

Latest Publications [Selected]

No new digest content identified.

Rand [to 28 June 2025]

<https://www.rand.org/pubs.html>

Published Research [Selected]

Research Jun 26, 2025

Protecting the Well-Being of Healthcare Workers During the COVID-19 Pandemic: The COVER-HCW Project

The Protecting the Well-Being of Healthcare Workers during the COVID-19 Pandemic Project examined the impact of a peer support program, Stress First Aid, on the mental well-being of healthcare workers during the COVID-19 pandemic.

Research Jun 26, 2025

The Incident Management Measurement Tool (IMMT): A Tool for Measuring Public Health Incident Management During and After Emergencies

Risks and priorities change during the management of public health incidents. We describe a new tool, the Incident Management Measurement Tool, that can be used to inform midcourse corrections during public health emergencies and realistic exercises.

Urban Institute [to 28 June 2025]

<https://www.urban.org/publications>

New Research Publications - Selected

World Economic Forum [to 28 June 2025]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....

.....

Public Consultations/Call for Inputs/Call for Papers

No new digest content identified.

* * * *

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the [Creative Commons Attribution 4.0 International License](http://creativecommons.org/licenses/by/4.0/). To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*
*

*
*

*
*

*
*